CL2018003269A1 - Ácidos carboxílicos para aplicación en la primera infancia. - Google Patents
Ácidos carboxílicos para aplicación en la primera infancia.Info
- Publication number
- CL2018003269A1 CL2018003269A1 CL2018003269A CL2018003269A CL2018003269A1 CL 2018003269 A1 CL2018003269 A1 CL 2018003269A1 CL 2018003269 A CL2018003269 A CL 2018003269A CL 2018003269 A CL2018003269 A CL 2018003269A CL 2018003269 A1 CL2018003269 A1 CL 2018003269A1
- Authority
- CL
- Chile
- Prior art keywords
- application
- carboxylic acids
- early childhood
- pharmaceutically acceptable
- carboxylic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE COMO INGREDIENTE ACTIVO UN ÁCIDO CARBOXÍLICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO PARA USAR PARA MEJORAR LA FUNCIÓN DE BARRERA CUTÁNEA, DONDE LA COMPOSICIÓN FARMACÉUTICA SE ADMINISTRA A UN LACTANTE. LA INVENCIÓN TAMBIÉN SE REFIERE A UN MÉTODO PARA TRATAR Y/O PREVENIR UNA ENFERMEDAD DE LA PIEL EN UN PACIENTE, EL MÉTODO COMPRENDE ADMINISTRAR UNA CANTIDAD EFECTIVA DE UN ÁCIDO CARBOXÍLICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO A UN PACIENTE QUE LO NECESITA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169888 | 2016-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003269A1 true CL2018003269A1 (es) | 2019-02-22 |
Family
ID=56014858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003269A CL2018003269A1 (es) | 2016-05-17 | 2018-11-16 | Ácidos carboxílicos para aplicación en la primera infancia. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190160030A1 (es) |
| EP (1) | EP3458044A1 (es) |
| JP (1) | JP2019516798A (es) |
| KR (1) | KR20190008236A (es) |
| CN (1) | CN109152755A (es) |
| AU (1) | AU2017266729A1 (es) |
| BR (1) | BR112018072183A2 (es) |
| CA (1) | CA3020558A1 (es) |
| CL (1) | CL2018003269A1 (es) |
| MX (1) | MX2018013474A (es) |
| RU (1) | RU2018143557A (es) |
| SG (1) | SG11201808487UA (es) |
| WO (1) | WO2017198705A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110403914A (zh) * | 2019-06-13 | 2019-11-05 | 兰溪市立顺生物有限公司 | 用于儿童早期应用的羧酸 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0617191D0 (en) * | 2006-08-31 | 2006-10-11 | York Pharma Plc | Improvements in pharmaceutical compositions |
| AU2007214300B2 (en) * | 2007-08-29 | 2009-11-05 | Sunny Pharmtech, Inc. | Method for Ameliorating Pruritus |
| US20130004590A1 (en) * | 2011-06-28 | 2013-01-03 | Lin Connie B | Zinc oxide/acid containing compositions and methods for treating and/or preventing enzymatic irritation |
-
2017
- 2017-05-17 WO PCT/EP2017/061835 patent/WO2017198705A1/en not_active Ceased
- 2017-05-17 CN CN201780030745.4A patent/CN109152755A/zh active Pending
- 2017-05-17 AU AU2017266729A patent/AU2017266729A1/en not_active Abandoned
- 2017-05-17 EP EP17723140.4A patent/EP3458044A1/en not_active Withdrawn
- 2017-05-17 SG SG11201808487UA patent/SG11201808487UA/en unknown
- 2017-05-17 US US16/097,746 patent/US20190160030A1/en not_active Abandoned
- 2017-05-17 MX MX2018013474A patent/MX2018013474A/es unknown
- 2017-05-17 RU RU2018143557A patent/RU2018143557A/ru not_active Application Discontinuation
- 2017-05-17 JP JP2019513482A patent/JP2019516798A/ja active Pending
- 2017-05-17 BR BR112018072183-2A patent/BR112018072183A2/pt not_active Application Discontinuation
- 2017-05-17 KR KR1020187033156A patent/KR20190008236A/ko not_active Withdrawn
- 2017-05-17 CA CA3020558A patent/CA3020558A1/en not_active Abandoned
-
2018
- 2018-11-16 CL CL2018003269A patent/CL2018003269A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018143557A (ru) | 2020-06-17 |
| KR20190008236A (ko) | 2019-01-23 |
| US20190160030A1 (en) | 2019-05-30 |
| EP3458044A1 (en) | 2019-03-27 |
| CA3020558A1 (en) | 2017-11-23 |
| AU2017266729A1 (en) | 2018-10-18 |
| JP2019516798A (ja) | 2019-06-20 |
| BR112018072183A2 (pt) | 2019-02-12 |
| SG11201808487UA (en) | 2018-10-30 |
| CN109152755A (zh) | 2019-01-04 |
| MX2018013474A (es) | 2019-08-12 |
| WO2017198705A1 (en) | 2017-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000270A (es) | Composiciones farmacéuticas tópicas | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| ECSP14013200A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| MX370361B (es) | Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético. | |
| MX389553B (es) | Composicion para incrementar la expresion de pgc-1alfa | |
| PE20151746A1 (es) | Compuestos biciclicos | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| AR109012A1 (es) | Sistema de administración transdérmica que contiene galantamina o sales de esta | |
| MX2019006773A (es) | Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros. | |
| CL2018003270A1 (es) | Una composición farmacéutica que comprende ácido carboxílico para tratar y prevenir congestión nasal. | |
| CO7121334A2 (es) | Formulaciones vesiculares | |
| CL2018003269A1 (es) | Ácidos carboxílicos para aplicación en la primera infancia. | |
| CL2018003268A1 (es) | Ácidos carboxílicos para tratar/prevenir una enfermedad de la piel. | |
| BR112017007863A2 (pt) | composição para o tratamento de condições envolvendo dor muscular | |
| AR101227A1 (es) | Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor | |
| NI201200196A (es) | Agentes terapéuticos 976 | |
| MX383214B (es) | COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACIÓN DE TRAUMA DE TEJIDO BLANDO. | |
| CL2016001952A1 (es) | Formulación farmacéutica tópica que comprende 50 a 2.500 ui/ml de sal de heparina, menos de o igual a 30% v/v de agua, 0% a 30% v/v de un alcohol de cadena inferior; y no menos de 45% v/v de un vehículo miscible en agua seleccionado del grupo que comprende propilenglicol, glicerol, glicofurol, polietilenglicol, o sus mezclas, util en tromboflebitis venosa superficial. | |
| ECSP15025570A (es) | Formulaciones de pidotimod | |
| CO2018000526A2 (es) | Concentrado que contiene alprostadil | |
| CR20160116A (es) | Método para tratar onicomicosis con hidroxipropil quitasano | |
| BR112016029761A8 (pt) | composições compreendendo um derivado de ácido quinolona carboxílico e agentes efervescentes, uso das mesmas e forma cristalina do referido derivado |